Eli Lilly pushes beyond GLP-1 with up to $3.8 billion in vaccine acquisitions

Eli Lilly is betting that the next major growth engine for its pipeline may come from vaccines, not blockbuster metabolic drugs. In late May, the company announced agreements to acquire three infectious-disease-focused biotech companies for a combined price that could reach about $3.8 billion, depending on future milestones. The deals are intended to expand Lilly’s research and development platform work in prevention, a strategy Lilly said is designed to reduce disease risk at the source rather than treating long-term downstream consequences.

Lilly’s first acquisition, Curevo Inc., centers on amezosvatein, an adjuvanted subunit vaccine candidate for shingles (also called herpes zoster) in adults. An adjuvanted subunit vaccine uses a small piece of a pathogen plus an “adjuvant,” a component designed to boost the immune response. Lilly said amezosvatein was engineered with a next-generation synthetic adjuvant to address tolerability challenges that can limit vaccination uptake and contribute to hesitancy about the second dose. In a Phase 2 head-to-head trial against the current standard of care, Lilly said amezosvatein matched immune response across primary endpoints and reduced side effects including fatigue, chills, and injection-site pain by more than half. Curevo shareholders could receive up to $1.5 billion in cash, including an upfront payment and additional milestone-based payments.

The second deal targets bacterial pathogens where antimicrobial resistance is narrowing treatment options, according to Lilly. The acquisition of LimmaTech Biologics AG would add vaccine programs against organisms including Staphylococcus aureus, Neisseria gonorrhoeae, and Chlamydia trachomatis. Lilly said LimmaTech’s proprietary platform is designed to generate broad, durable immune responses by targeting toxins and superantigens that drive disease. Its lead program, LTB-SA7, is in Phase 1 development as a vaccine against S. aureus, a leading cause of surgical-site infection. LimmaTech shareholders could receive up to $780 million in cash, also tied to upfront and clinical and regulatory milestones.

The third acquisition is Vaccine Company, Inc., which Lilly said is developing proprietary In Vivo Nanoparticle (IVN) technology. IVN is described by Lilly as a way to display antigens in vivo to elicit immune responses associated with virus-like particle (VLP) vaccines while avoiding what it calls the manufacturing burden of traditional VLP production. Lilly said the company’s lead program applies the technology to Epstein-Barr virus (EBV) with a five-antigen Phase 1-ready candidate. Lilly linked EBV to multiple sclerosis and several malignancies, saying a prophylactic vaccine could reduce not only acute infectious mononucleosis but also potential long-term neurological and oncological consequences. Vaccine Company shareholders could receive up to $1.55 billion in cash, with payments contingent on clinical and commercial milestones.

Taken together, the three deal maxima imply an overall purchase price of roughly $3.83 billion, which lines up with the “$3.8 billion” figure that has circulated in investor commentary. Lilly said the transactions are subject to customary closing conditions, including expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the U.S. antitrust pre-merger notification process). It also said it will determine the accounting treatment under generally accepted accounting principles and that the transactions would be reflected in financial results and financial guidance after closing.

Market attention on Lilly in recent months has been dominated by its GLP-1 franchise, including Mounjaro and Zepbound, and by the broader question of how long that category leadership can last. In a recent write-up, The Motley Fool argued that investors may be focusing too narrowly on near-term GLP-1 performance while missing what it described as Lilly’s long-range effort to diversify into infectious disease prevention.

What Lilly did not fully disclose in the announcement is just as important as what it did. The press release did not provide a timeline for closing these transactions beyond the mention of antitrust waiting periods, and it did not offer detailed financial terms such as the size of the upfront portions versus milestone-heavy payments for each deal. It also did not provide any clinical results beyond the Phase 2 comparison for amezosvatein, nor did it characterize the probability-weighted odds of reaching later milestones. As with most vaccine candidates, the programs are still investigational, and the company did not indicate whether any of the platforms have already validated manufacturing scalability or durability at scale for the specific targets in these candidates.

Investors and analysts are likely to watch for several follow-on items. First, Lilly will need to clear the Hart-Scott-Rodino process and satisfy other standard closing conditions. Second, the company’s integration of three different platform approaches into one infectious-disease strategy will be a near- to medium-term storyline, particularly as it allocates resources alongside its metabolic franchise. Finally, early clinical readouts for the Phase 1 and Phase 1-ready candidates could determine whether the acquisitions produce credible leads for follow-on development.